Compare DexCom, Inc. (DXCM) vs Noble Corporation plc (NE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Noble Corporation plc — how do they compare? DexCom, Inc. trades at $78.55 (market cap $28.06B), while Noble Corporation plc trades at $41.03 (market cap $6.47B). The key difference: DexCom, Inc. is far larger — about 4.3× Noble Corporation plc's market cap, and Noble Corporation plc pays a 4.93% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | NE | |
|---|---|---|
Market Cap | $28.06B | $6.47B |
Sector | Health | Technology |
52-Week High | $89.53 | $54.37 |
52-Week Low | $54.84 | $25.70 |
Enterprise Value | $27.03B | $7.73B |
Dividend Yield | — | 4.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Noble Corporation (NE) trades at $40.92, down 1.82% on the day, with a bullish technical outlook supported by moving averages despite recent earnings volatility. The company maintains solid fundamentals with a P/E of 28.38 and net income margin of 7.17%, while recent news highlights contract wins like a $136.2M Brunei drilling deal (Zacks Investment Research, 2026-07-14). Cash flow remains positive, with net cash flow of $227.68M in 2025.
The stock offers upside to the $49.75 analyst consensus target, but risks include earnings misses in two of the last three quarters and competitive pressures in offshore drilling. Investor sentiment is mixed, with 31% of analysts rating it Buy amid technical overbought signals, requiring caution near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →
